F R Hirsch
Overview
Explore the profile of F R Hirsch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
1519
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meyer M, Peters S, Mok T, Lam S, Yang P, Aggarwal C, et al.
Ann Oncol
. 2024 Oct;
35(12):1088-1104.
PMID: 39413875
Background: Lung cancer remains a critical public health issue, presenting multifaceted challenges in prevention, diagnosis, and treatment. This article aims to review the current landscape of lung cancer research and...
2.
Ren S, Wang J, Ying J, Mitsudomi T, Lee D, Chu Q, et al.
ESMO Open
. 2022 Apr;
7(3):100482.
PMID: 35461023
No abstract available.
3.
Ren S, Wang J, Ying J, Mitsudomi T, Lee D, Chu Q, et al.
ESMO Open
. 2022 Feb;
7(1):100395.
PMID: 35149428
Human epidermal growth factor receptor 2 (HER2) is a transmembrane glycoprotein receptor with intracellular tyrosine kinase activity. Its alterations, including mutation, amplification and overexpression, could result in oncogenic potential and...
4.
Wang Y, Jiang T, Qin Z, Jiang J, Wang Q, Yang S, et al.
Ann Oncol
. 2019 Jan;
30(3):447-455.
PMID: 30596880
Background: Effective targeted therapy for non-small-cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) mutations remains an unmet need. This study investigated the antitumor effect of...
5.
Bonomi P, Gandara D, Hirsch F, Kerr K, Obasaju C, Paz-Ares L, et al.
Ann Oncol
. 2018 Jun;
29(8):1701-1709.
PMID: 29905778
Background: Upregulated expression and aberrant activation of the epidermal growth-factor receptor (EGFR) are found in lung cancer, making EGFR a relevant target for non-small-cell lung cancer (NSCLC). Treatment with anti-EGFR...
6.
Paz-Ares L, Socinski M, Shahidi J, Hozak R, Soldatenkova V, Kurek R, et al.
Ann Oncol
. 2016 May;
27(8):1573-9.
PMID: 27207107
Background: SQUIRE demonstrated addition of necitumumab to gemcitabine and cisplatin significantly improved survival in patients with stage IV sq-NSCLC. Here, we report additional outcomes for the subpopulation of patients with...
7.
Steuer C, Papadimitrakopoulou V, Herbst R, Redman M, Hirsch F, Mack P, et al.
Clin Pharmacol Ther
. 2015 Feb;
97(5):488-91.
PMID: 25676724
Although the proportion of patients with squamous cell carcinoma of the lung has declined over the last two decades, the disease is still fatal for tens of thousands of patients...
8.
Christoph D, Kasper S, Gauler T, Loesch C, Engelhard M, Theegarten D, et al.
Br J Cancer
. 2012 Jul;
107(5):823-30.
PMID: 22836512
Background: Tubulin-binding agents (TBAs) are effective in non-small cell lung cancer (NSCLC) treatment. Both βIII- and βV-tubulins are expressed by cancer cells and may lead to resistance against TBAs. Methods:...
9.
Brodowicz T, Ciuleanu T, Crawford J, Filipits M, Fischer J, Georgoulias V, et al.
Ann Oncol
. 2011 Sep;
23(5):1223-1229.
PMID: 21940784
The current third consensus on the systemic treatment of non-small-cell lung cancer (NSCLC) builds upon and updates similar publications on the subject by the Central European Cooperative Oncology Group (CECOG),...
10.
Arriola E, Canadas I, Arumi-Uria M, Domine M, Lopez-Vilarino J, Arpi O, et al.
Br J Cancer
. 2011 Aug;
105(6):814-23.
PMID: 21847116
Background: Small cell lung carcinoma (SCLC) has poor prognosis and remains orphan from targeted therapy. MET is activated in several tumour types and may be a promising therapeutic target. Methods:...